XBiotech Inc. XBIT
XBiotech Inc. ("XBiotech" or the "Company") is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies for treating a variety of diseases. XBiotech was incorporated in Canada on March 22, 2005. The Company's Internet address is www.xbiotech.com. The Company makes available free of charge on or through its website its annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as well as proxy statements, as soon as reasonably practicable after the Company electronically files such material with, or furnishes it to, the Securities and Exchange Commission. The Company's website is included in this annual report on Form 10-K as an inactive textual reference only. The information on, or accessible through, the Company's website is not a part of, or incorporated by reference in, this annual report on Form 10-K. The SEC maintains an Internet site that contains these reports at http://www.sec.gov.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $4.0M | $18.4M | $44.0M | $0 | $0 | — | — |
| Cost of revenue | — | — | $0 | $651.0K | $5.8M | $34.5M | $0 | $0 | — | — |
| Gross profit | — | — | $0 | $3.4M | $12.6M | $9.4M | $0 | $0 | — | — |
| R&D | $47.4M | $37.8M | $32.8M | $31.5M | $28.3M | $9.5M | $24.1M | $15.7M | $26.4M | $42.5M |
| SG&A | $8.3M | $4.7M | $4.7M | $6.3M | $9.4M | $18.2M | $7.1M | $5.3M | $7.6M | $10.3M |
| Total operating expenses | — | $42.5M | $37.5M | $37.8M | $37.7M | $27.7M | $31.2M | $21.0M | $34.1M | $52.8M |
| Operating income | -$55.7M | -$42.5M | -$37.5M | -$34.5M | -$25.1M | -$18.3M | -$31.2M | -$21.0M | -$34.1M | -$52.8M |
| Pre-tax income | -$45.3M | -$38.6M | -$24.3M | -$33.6M | -$25.5M | -$12.8M | $718.5M | -$21.1M | -$33.1M | -$52.8M |
| Income tax | $235.0K | $32.0K | $244.0K | $688.0K | $8.0M | $1.6M | $49.8M | $0 | $0 | $0 |
| Net income | -$45.5M | -$38.5M | -$24.6M | -$32.9M | -$17.4M | -$11.2M | $668.6M | -$21.1M | -$33.1M | -$52.8M |
| EPS, basic | -1.49 | -1.26 | -0.81 | -1.08 | -0.58 | -0.36 | 17.17 | -0.59 | -0.95 | — |
| EPS, diluted | -1.49 | -1.26 | -0.81 | -1.08 | -0.58 | -0.36 | 14.44 | -0.59 | -0.95 | -1.63 |
| Shares, diluted (wtd. avg.) | $30.5M | $30.5M | $30.4M | $30.4M | $30.0M | $30.8M | $46.3M | $35.8M | $34.9M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $125.6M | $172.7M | $200.0M | $157.3M | $237.0M | $237.4M | $714.6M | $15.8M | $31.8M | $34.3M |
| Short-term investments | — | — | $0 | $60.2M | $0 | — | — | — | — | — |
| Receivables | — | — | — | — | $0 | $4.1M | $0 | — | — | — |
| Total current assets | $127.0M | $174.6M | $201.7M | $219.8M | $246.9M | $325.9M | $716.3M | $17.0M | $33.3M | $36.9M |
| Property, plant and equipment | $23.1M | $24.5M | $24.9M | $26.3M | $28.3M | $27.3M | $25.2M | $27.3M | $29.6M | $10.1M |
| Total assets | $150.1M | $199.1M | $226.6M | $246.1M | $275.2M | $353.7M | $816.9M | $44.3M | $63.0M | $67.0M |
| Accounts payable | $1.5M | $2.2M | $2.5M | $2.4M | $2.1M | $2.5M | $2.1M | $1.7M | $1.7M | $4.4M |
| Total current liabilities | $7.9M | $15.1M | $6.1M | $4.1M | $3.5M | $4.0M | $60.2M | $2.9M | $2.8M | $8.0M |
| Total liabilities | $9.7M | $16.8M | $7.8M | $5.7M | $5.8M | $5.1M | $61.2M | $2.9M | $2.8M | $8.0M |
| Retained earnings | -$136.4M | -$90.8M | -$52.3M | -$27.7M | $5.2M | $97.6M | $430.9M | -$237.7M | -$216.6M | -$183.4M |
| Total equity | $140.3M | $182.3M | $218.8M | $240.4M | $269.4M | $348.6M | $755.6M | $41.4M | $60.2M | $59.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.9M | -$31.0M | -$18.7M | -$14.8M | $69.4M | -$65.1M | -$18.3M | -$16.5M | -$33.6M | -$46.0M |
| Depreciation and amortisation | $1.7M | $1.7M | $1.7M | $2.6M | $2.6M | $2.2M | $2.4M | $2.4M | $1.5M | $698.0K |
| Stock-based compensation | $3.6M | $1.8M | $3.3M | $5.1M | $4.5M | $12.6M | $3.4M | $1.7M | $1.8M | $5.6M |
| Capital expenditure | $289.0K | $1.3M | $362.0K | $585.0K | $3.5M | $3.7M | $204.0K | $122.0K | $1.4M | $4.7M |
| Investing cash flow | -$289.0K | -$1.3M | $61.5M | -$63.9M | -$3.5M | -$3.7M | $674.8M | -$122.0K | -$1.4M | -$13.9M |
| Financing cash flow | -$10.2M | $10.4M | -$9.0K | $0 | -$67.0M | -$409.7M | $42.1M | $201.0K | $33.3M | $2.9M |
| Dividends paid | — | — | — | $0 | $75.0M | $0 | $0 | — | — | — |
| Buybacks | — | $0 | $14.0K | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001171843-26-002814.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |